Vir Biotechnology, Inc. (NASDAQ:VIR) Holdings Cut by Quantbot Technologies LP

Quantbot Technologies LP reduced its stake in shares of Vir Biotechnology, Inc. (NASDAQ:VIR) by 20.8% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 14,620 shares of the company’s stock after selling 3,832 shares during the period. Quantbot Technologies LP’s holdings in Vir Biotechnology were worth $107,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Teacher Retirement System of Texas grew its stake in shares of Vir Biotechnology by 10.7% in the 4th quarter. Teacher Retirement System of Texas now owns 26,440 shares of the company’s stock valued at $194,000 after buying an additional 2,556 shares in the last quarter. Tejara Capital Ltd acquired a new stake in Vir Biotechnology in the fourth quarter valued at approximately $381,000. Amundi grew its position in Vir Biotechnology by 224.3% in the fourth quarter. Amundi now owns 46,614 shares of the company’s stock worth $342,000 after acquiring an additional 32,241 shares in the last quarter. PNC Financial Services Group Inc. increased its stake in shares of Vir Biotechnology by 31.8% during the 4th quarter. PNC Financial Services Group Inc. now owns 8,288 shares of the company’s stock worth $61,000 after purchasing an additional 1,999 shares during the last quarter. Finally, Victory Capital Management Inc. raised its holdings in shares of Vir Biotechnology by 9.2% during the 4th quarter. Victory Capital Management Inc. now owns 88,776 shares of the company’s stock valued at $652,000 after purchasing an additional 7,507 shares in the last quarter. 65.32% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Vir Biotechnology

In other news, EVP Verneuil Vanina De sold 7,373 shares of the business’s stock in a transaction that occurred on Wednesday, February 26th. The stock was sold at an average price of $9.14, for a total transaction of $67,389.22. Following the sale, the executive vice president now directly owns 79,460 shares in the company, valued at approximately $726,264.40. The trade was a 8.49 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director George A. Scangos sold 10,964 shares of the firm’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $9.81, for a total value of $107,556.84. Following the completion of the transaction, the director now directly owns 708,295 shares of the company’s stock, valued at approximately $6,948,373.95. This trade represents a 1.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 30,859 shares of company stock valued at $326,458 in the last ninety days. Company insiders own 15.60% of the company’s stock.

Analysts Set New Price Targets

VIR has been the subject of a number of recent research reports. HC Wainwright reissued a “buy” rating and set a $110.00 target price on shares of Vir Biotechnology in a research report on Friday, February 28th. Morgan Stanley raised Vir Biotechnology from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $10.00 to $20.00 in a report on Thursday, January 9th. Leerink Partners boosted their target price on Vir Biotechnology from $18.00 to $20.00 and gave the stock an “outperform” rating in a report on Monday, January 13th. Needham & Company LLC reiterated a “buy” rating and set a $19.00 price target on shares of Vir Biotechnology in a report on Thursday, February 27th. Finally, Barclays lifted their price target on shares of Vir Biotechnology from $26.00 to $31.00 and gave the company an “overweight” rating in a research report on Friday, February 28th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $35.67.

Vir Biotechnology Stock Down 3.3 %

Shares of NASDAQ:VIR opened at $6.48 on Tuesday. The company has a market cap of $888.69 million, a price-to-earnings ratio of -1.65 and a beta of 1.17. The business has a 50 day moving average price of $8.73 and a 200 day moving average price of $8.35. Vir Biotechnology, Inc. has a twelve month low of $6.25 and a twelve month high of $14.45.

Vir Biotechnology (NASDAQ:VIR) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($0.76) earnings per share for the quarter, beating the consensus estimate of ($0.85) by $0.09. The company had revenue of $12.37 million during the quarter, compared to analysts’ expectations of $8.14 million. Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%. Analysts anticipate that Vir Biotechnology, Inc. will post -3.92 EPS for the current year.

Vir Biotechnology Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).